{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:07:38Z","timestamp":1771034858185,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1124\/dmd.124.001798","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T16:35:14Z","timestamp":1730478914000},"page":"1388-1395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-5844","authenticated-orcid":false,"given":"Mikael O.W.","family":"Piha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"Cajanus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica T.","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-1638","authenticated-orcid":false,"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troels K.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-2189","authenticated-orcid":false,"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2788","authenticated-orcid":false,"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8265","authenticated-orcid":false,"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-5692","authenticated-orcid":false,"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.124.001798_bib1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.5414\/CP201528","article-title":"Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide","volume":"49","author":"Aberg","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bioorg.2008.02.004","article-title":"Enzyme-assisted synthesis and structure characterization of glucuronic acid conjugates of losartan, candesartan, and zolarsartan","volume":"36","author":"Alonen","year":"2008","journal-title":"Bioorg Chem"},{"key":"10.1124\/dmd.124.001798_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","article-title":"The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan","volume":"76","author":"Alonen","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.124.001798_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.124.001798_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2010.19","article-title":"Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer","volume":"11","author":"Bergmann","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.124.001798_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bcp.12795","article-title":"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma","volume":"81","author":"Bergmann","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.124.001798_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","article-title":"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide","volume":"56","author":"Bidstrup","year":"2003","journal-title":"Brit J Clinical Pharma"},{"key":"10.1124\/dmd.124.001798_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5414\/CP201879","article-title":"Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions","volume":"51","author":"Brendel","year":"2013","journal-title":"CP"},{"key":"10.1124\/dmd.124.001798_bib10","first-page":"749","article-title":"Differential clinical profile of candesartan compared to other angiotensin blockers","volume":"7","author":"Cernes","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1124\/dmd.124.001798_bib11","unstructured":"European Medicines Agency, Committee for Human Medicinal Products (2012) Guideline on the investigation of drug interactions (CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2**)."},{"key":"10.1124\/dmd.124.001798_bib12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","volume":"61","author":"Gatti","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.124.001798_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/j.1875-9114.1998.tb03137.x","article-title":"Repaglinide, A Novel, Short-Acting Hypoglycemic Agent for Type 2 Diabetes Mellitus","volume":"18","author":"Guay","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.124.001798_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpdd.787","article-title":"Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy Subjects","volume":"10","author":"Gundlach","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.124.001798_bib17","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1124\/dmd.111.040931","article-title":"Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses","volume":"39","author":"Honkalammi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/tx800491e","article-title":"Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database","volume":"22","author":"Isoherranen","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.124.001798_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/dmd.118.084665","article-title":"Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans","volume":"47","author":"Itkonen","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1124\/dmd.105.003715","article-title":"Impact of Parallel Pathways of Drug Elimination and Multiple Cytochrome P450 Involvement on Drug-Drug Interactions: CYP2D6 Paradigm","volume":"33","author":"Ito","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"10.1124\/dmd.124.001798_bib22","article-title":"Pharmacokinetic drug interaction studies with candesartan cilexetil","volume":"11","author":"Jonkman","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/dmd.124.001798_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106735","article-title":"Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors","volume":"198","author":"Kahma","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.124.001798_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.124.001798_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5414\/CP203180","article-title":"Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia","volume":"56","author":"Katsube","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.120.000126","article-title":"In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-\u03b2-D-glucuronide in the Liver","volume":"49","author":"Katsube","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib27","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/DDDT.S172568","article-title":"No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects","volume":"12","author":"Kim","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.124.001798_bib28","first-page":"594","article-title":"Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs","volume":"46","author":"Kondo","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.124.001798_bib29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1096-9888(199608)31:8<873::AID-JMS368>3.0.CO;2-J","article-title":"Characterization of Conjugated Metabolites of a New Angiotensin II Receptor Antagonist, Candesartan Cilexetil, in Rats by Liquid Chromatography\/Electrospray Tandem Mass Spectrometry Following Chemical Derivatization","volume":"31","author":"Kondo","year":"1996","journal-title":"J Mass Spectrom"},{"key":"10.1124\/dmd.124.001798_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2710.2009.01053.x","article-title":"Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients","volume":"34","author":"Miura","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/dmd.124.001798_bib31","unstructured":"National Center for Biotechnology Information (2023a) PubChem Compound Summary for CID 2541, Candesartan."},{"key":"10.1124\/dmd.124.001798_bib32","unstructured":"National Center for Biotechnology Information (2023b) PubChem Compound Summary for CID 131769984, Candesartan O-glucuronide."},{"key":"10.1124\/dmd.124.001798_bib33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","article-title":"Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics","volume":"77","author":"Niemi","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1124\/dmd.124.001798_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/bdd.440","article-title":"Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients","volume":"26","author":"Pietruck","year":"2005","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.124.001798_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In silico\u2019 simulations to assess the \u2018in vivo\u2019 consequences of \u2018in vitro\u2019 metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/dmd.124.001798_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bcpt.12789","article-title":"Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes","volume":"121","author":"Senda","year":"2017","journal-title":"Basic Clin Pharma Tox"},{"key":"10.1124\/dmd.124.001798_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.124.001798_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.09.002","article-title":"Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review","volume":"141","author":"Stingl","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002280050731","article-title":"In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists","volume":"56","author":"Taavitsainen","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.124.001798_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcpt.13647","article-title":"Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel","volume":"130","author":"Tornio","year":"2022","journal-title":"Basic Clin Pharma Tox"},{"key":"10.1124\/dmd.124.001798_bib44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib45","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib46","unstructured":"United States Food and Drug Administration. (2023) Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers."},{"key":"10.1124\/dmd.124.001798_bib47","unstructured":"United States Food and Drug Administration, Center for Drug Evaluation and Research (1998) Atacand clinical pharmacology and biopharmaceutics review. NDA 20-838:1-30."},{"key":"10.1124\/dmd.124.001798_bib48","unstructured":"United States Food and Drug Administration, Center for Drug Evaluation and Research. (2020) In vitro drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions: guidance for industry."},{"key":"10.1124\/dmd.124.001798_bib49","first-page":"66","article-title":"The role of metabolites in predicting drug-drug interactions: focus on irreversible P450 inhibition","volume":"13","author":"VandenBrink","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/dmd.124.001798_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","article-title":"Examination of 209 drugs for inhibition of cytochrome P450 2C8","volume":"45","author":"Walsky","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.124.001798_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001798_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of Intestinal First-Pass Drug Metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.124.001798_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.2010.252","article-title":"Are Circulating Metabolites Important in Drug-Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency","volume":"89","author":"Yeung","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001798_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.108.023648","article-title":"Relationship between Drug\/Metabolite Exposure and Impairment of Excretory Transport Function","volume":"37","author":"Zamek-Gliszczynski","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.124.001798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:19:23Z","timestamp":1743653963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624159429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0090955624159429"],"URL":"https:\/\/doi.org\/10.1124\/dmd.124.001798","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.124.001798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}